Page 90 - 80_01

Jorge
Enrique
Machado-­-Alba

48.
Nanda
KS,
Cheifetz
AS,
Moss
AC.
Impact
of
antibodies
to
infliximab
on
clinical
outcomes

and
serum
infliximab
levels
in
patients
with
inflammatory
bowel
disease
(IBD):
a
meta-­-
analysis.
Am
J
Gastroenterol
108(1),
40-­-7
(2013).

49.
Rodgers
M,
Epstein
D,
Bojke
L,
Yang
H,
Craig
D,
Fonseca
T,
et
al.
Etanercept,
infliximab
and

adalimumab
for
the
treatment
of
psoriatic
arthritis:
a
systematic
review
and
economic

evaluation.
Health
Technol
Assess
15(10),
1-­-329
(2011).

50.
Burmester
GR,
Panaccione
R,
Gordon
KB,
McIlraith
MJ,
Lacerda
AP.
Adalimumab:
long-­-term

safety
in
23
458
patients
from
global
clinical
trials
in
rheumatoid
arthritis,
juvenile

idiopathic
arthritis,
ankylosing
spondylitis,
psoriatic
arthritis,
psoriasis
and
Crohn's

disease.
Ann
Rheum
Dis
72(4),
517-­-24
(2013).

51.
Aaltonen
KJ,
Virkki
LM,
Malmivaara
A,
Konttinen
YT,
Nordström
DC,
Blom
M.
Systematic

review
and
meta-­-analysis
of
the
efficacy
and
safety
of
existing
TNF
blocking
agents
in

treatment
of
rheumatoid
arthritis.
PLoS
One
7(1),
e30275
(2012).

52.
Agarwal
SK.
Biologic
agents
in
rheumatoid
arthritis:
an
update
for
managed
care

professionals.
J
Manag
Care
Pharm
17(9
Suppl
B),
S14-­-8
(2011).

53.
Simsek
I.
TNF
inhibitors
-­-
new
and
old
agents
for
rheumatoid
arthritis.
Bull
NYU
Hosp
Jt
Dis

68(3),
204-­-10
(2010).

54.
Singh
JA,
Cameron
DR.
Summary
of
AHRQ's
comparative
effectiveness
review
of
drug

therapy
for
rheumatoid
arthritis
(RA)
in
adults-­--­-an
update.
J
Manag
Care
Pharm
18(4

Supp
C),
S1-­-18
(2012).

55.
Herrero-­-Beaumont
G,
Martínez
Calatrava
MJ,
Castañeda
S.
Abatacept
mechanism
of
action:

concordance
with
its
clinical
profile.
Reumatol
Clin
8(2),
78-­-83
(2012).

56.
Guyot
P,
Taylor
P,
Christensen
R,
Pericleous
L,
Poncet
C,
Lebmeier
M,
et
al.
Abatacept
with

methotrexate
versus
other
biologic
agents
in
treatment
of
patients
with
active
rheumatoid

arthritis
despite
methotrexate:
a
network
meta-­-analysis.
Arthritis
Res
Ther
13(6),
R204

(2011).

57.
Reichert
JM.
Marketed
therapeutic
antibodies
compendium.
MAbs
4(3),
413-­-5
(2012).

58.
Wenzel
S,
Ford
L,
Pearlman
D,
Spector
S,
Sher
L,
Skobieranda
F,
et
al.
Dupilumab
in

Persistent
Asthma
with
Elevated
Eosinophil
Levels.
N
Engl
J
Med
368(26),
2455-­-66

(2013).

59.
Lebre
MC,
Jonckheere
CL,
Kraan
MC,
van
Kuijk
AW,
Bos
JD,
de
Rie
M,
et
al.
Expression
of
IL-­-
20
in
synovium
and
lesional
skin
of
patients
with
psoriatic
arthritis:
differential
response

to
alefacept
treatment.
Arthritis
Res
Ther
14(5),
R200
(2012).

60.
Sandborn
WJ,
Gasink
C,
Gao
LL,
Blank
MA,
Johanns
J,
Guzzo
C,
et
al;
CERTIFI
Study
Group.

Ustekinumab
induction
and
maintenance
therapy
in
refractory
Crohn's
disease.
N
Engl
J

Med
367(16),
1519-­-28
(2012).

61.
Migone
TS,
Subramanian
GM,
Zhong
J,
Healey
LM,
Corey
A,
Devalaraja
M,
et
al.

Raxibacumab
for
the
treatment
of
inhalational
anthrax.
N
Engl
J
Med
361(2),
135-­-44

(2009).

62.
Mazumdar
S.
Raxibacumab.
MAbs
1(6),
531-­-8
(2009).

63.
Ruf
P,
Kluge
M,
Jäger
M,
Burges
A,
Volovat
C,
Heiss
MM,
et
al.
Pharmacokinetics,

immunogenicity
and
bioactivity
of
the
therapeutic
antibody
catumaxomab

intraperitoneally
administered
to
cáncer
patients.
Br
J
Clin
Pharmacol
69(6),
617-­-25

(2010).

64.
Xu
L,
Kohli
N,
Rennard
R,
Jiao
Y,
Razlog
M,
Zhang
K,
et
al.
Rapid
optimization
and

prototyping
for
therapeutic
antibody-­-like
molecules.
MAbs
5(2),
237-­-54
(2013)

65.
Sebastian
M.
Review
of
catumaxomab
in
the
treatment
of
malignant
ascites.
Cancer
Manag

Res
2,
283-­-6
(2010).

66.
Seimetz
D.
Novel
monoclonal
antibodies
for
cancer
treatment:
the
trifunctional
antibody

catumaxomab
(removab).
J
Cancer
2,
309-­-16
(2011).

67.
Diaz
JF,
Cardenal
R,
Gomez-­-Manchero
A,
Sanchez-­-Gonzalez
C.
Safety
and
efficacy
of

tirofiban
as
adjunctive
therapy
for
patients
with
ST-­-elevation
myocardial
infarction:
a

comparison
versus
placebo
and
abciximab.
Cardiovasc
Hematol
Agents
Med
Chem
9(3),

147-­-53
(2011).

68.
Michelson
AD.
Advances
in
antiplatelet
therapy.
Hematology
Am
Soc
Hematol
Educ

Program
2011,
62-­-9
(2011).

69.
Klamová
H,
Poláková
KM,
Mužík
J,
Rácil
Z,
Zácková
D,
Steinerová
K,
et
al.
Evaluation
of
5-­-
year
imatinib
treatment
of
458
patients
with
CP-­-CML
in
routine
clinical
practice
and

prognostic
impact
of
different
BCR-­-ABL
cutoff
levels.
Cancer
Med
2(2),
216-­-25
(2013).

88